ABERA BIOSCIENCE AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.71 SEK | -1.26% |
|
-1.67% | -8.72% |
| Sales 2023 | 2.65M 240K | Sales 2024 * | 15.9M 1.44M | Capitalization | 72.31M 6.55M |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 | 28.2 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 4.55 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 6 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 57.87% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.26% | ||
| 1 week | -1.67% | ||
| Current month | -2.89% | ||
| 1 month | -2.89% | ||
| 3 months | +3.52% | ||
| 6 months | +17.75% | ||
| Current year | -8.72% |
1 week
4.45
4.98
1 month
4.325.86
Current year
3.897.50
1 year
3.057.50
3 years
3.0530.80
5 years
3.0530.80
10 years
3.0530.80
| Managers | Title | Age | Since |
|---|---|---|---|
Maria Alriksson
CEO | Chief Executive Officer | 41 | 20-09-30 |
Joen Luirink
FOU | Founder | 64 | 12-11-02 |
| Chief Tech/Sci/R&D Officer | 59 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 19-12-31 | |
| Chairman | 54 | 14-12-31 | |
Joen Luirink
FOU | Founder | 64 | 12-11-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 4.71 | -1.26% | 4,079 |
| 24-04-29 | 4.77 | +3.70% | 23,915 |
| 24-04-26 | 4.6 | -2.95% | 21,927 |
| 24-04-25 | 4.74 | +2.16% | 6,885 |
| 24-04-24 | 4.64 | -3.33% | 3,952 |
End-of-day quote NORDIC GROWTH MARKET, April 29, 2024
More quotes
Abera Bioscience AB is a Sweden-based company, which is active in biotechnology. Abera Bioscience is platform and vaccine development company active in the medical, molecular and microbiological field. The Companyâs purpose is to develop vaccine candidates based on its vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines. The technology is mainly used in the development of new vaccines where the focus is on the main areas of pneumococci and immunooncology. The business is located around the Nordic market.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.72% | 6.58M | |
| +0.17% | 42.19B | |
| +10.92% | 42.24B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.23% | 24.63B | |
| -24.79% | 18.2B | |
| +26.69% | 12.01B | |
| -3.13% | 11.76B | |
| +6.57% | 10.4B |
- Stock Market
- Equities
- ABERA Stock
